Heterochromatin marks HP1γ, HP1α and H3K9me3, and DNA damage response activation in human testis development and germ cell tumours

International Journal of Andrology

Volumn 34, Issue 4 PART 2, 2011, Pages

  Bartkova, J ^a   Moudry, P ^b   Hodny, Z ^b   Lukas, J ^a   Rajpert De Meyts, E ^c   Bartek, J ^a,b  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^c Rigshospitalet   (Denmark)

Author keywords

DNA damage response; Heterochromatin; Heterochromatin protein 1; Spermatogenesis; Testicular germ cell neoplasms; Trimethylated histone H3 at lysine 9

Indexed keywords

DNA; GAMMA HISTONE H2AX; HETEROCHROMATIN PROTEIN 1; HETEROCHROMATIN PROTEIN 1 ALPHA; HETEROCHROMATIN PROTEIN 1 GAMMA; HISTONE H2AX; HISTONE H3; HISTONE H3 TRIMETHYLATED AT LYSINE 9; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARCINOGENESIS; CARCINOMA IN SITU; CELL AGING; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; EMBRYONAL CARCINOMA; FETUS; GENETIC MARKER; GERM CELL; GERM CELL TUMOR; GONOCYTE; HETEROCHROMATIN; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MALE; NERVE CELL DIFFERENTIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEMINOMA; SENESCENCE; TERATOMA; TESTIS DEVELOPMENT;

ANTIBODIES, MONOCLONAL; CELL AGING; CELL LINE; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA DAMAGE; DNA REPAIR; FLUORESCENT ANTIBODY TECHNIQUE; HETEROCHROMATIN; HISTONES; HUMANS; IMMUNOBLOTTING; MALE; METHYLATION; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; TESTICULAR NEOPLASMS; TESTIS;

EID: 79851471744     PISSN: 01056263     EISSN: 13652605     Source Type: Journal    
DOI: 10.1111/j.1365-2605.2010.01096.x     Document Type: Article

References (49)

1. Aagaard L, Lukas J, Bartkova J, Kjerulff A-A, Strauss M & Bartek J. (1995) Aberrations of p16Ink4 and retinoblastoma tumour-suppressor genes occur in distinct sub-sets of human cancer cell lines. Int J Cancer 61, 115-120.
2. Ahmed EA, Van Der Vaart A, Barten A, Kal HB, Chen J, Lou Z et al. (2007) Differences in DNA double strand breaks repair in male germ cell types: lessons learned from a differential expression of Mdc1 and 53BP1. DNA Repair (Amst) 6, 1243-1254.
3. Andrews PW. (1998) Teratocarcinomas and human embryology: pluripotent human EC cell lines. APMIS 106, 158-168.
4. Bartek J, Bartkova J & Lukas J. (2007) DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 26, 7773-7779.
5. Bartkova J, Lukas C, Sørensen CS, Rajpert-De Meyts E, Skakkebæk NE, Lukas J & Bartek J. (2003a) Deregulation of the RB pathway in human testicular germ cell tumors. J Pathol 200, 149-156.
6. Bartkova J, Rajpert-De Meyts E, Skakkebaek NE, Lukas J & Bartek J. (2003b) Deregulation of the G1/S-phase control in human testicular germ cell tumours. APMIS 111, 252-265.
7. Bartkova J, Bakkenist CJ, Rajpert-De Meyts E, Skakkebaek NE, Sehested M, Lukas J et al. (2005a) ATM activation in normal human tissues and testicular cancer. Cell Cycle 4, 838-845.
8. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested P, Nesland M, Lukas C et al. (2005b) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434, 864-870.
9. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N et al. (2006) Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444, 633-637.
10. Bartkova J, Rajpert-De Meyts E, Skakkebaek NE, Lukas J & Bartek J. (2007a) DNA damage response in human testes and testicular germ cell tumours: biology and implications for therapy. Int J Androl 30, 282-291.
11. Bartkova J, Horejsi Z, Sehested M, Nesland JM, Rajpert-De Meyts E, Skakkebaek NE, Stucki M, Jackson SP, Lukas J & Bartek J. (2007b) DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene 26, 7414-7422.
12. Bartkova J, Tommiska J, Oplustilova L, Aaltonen K, Tamminen A, Heikkinen T et al. (2008) Aberrations of the Mre11-Rad50-Nbs1 DNA damage sensor complex in human breast cancer: Mre11 as a candidate familial cancer-predisposing gene. Mol Oncol 2, 296-316.
13. Bekker-Jensen S, Lukas C, Melander F, Bartek J & Lukas J. (2005) Dynamic assembly and sustained retention of 53BP1 at the sites of DNA damage are controlled by Mdc1/NFBD1. J Cell Biol 170, 201-211.
14. Blazkova H, Krejcikova K, Moudry P, Frisan T, Hodny Z & Bartek J. (2009) Bacterial intoxication evokes cellular senescence with persistent DNA damage and cytokine signaling. J Cell Mol Med 14, 357-367.
15. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegerberger B, Stein H, Dorken B, Jenuwein T & Schmitt CA. (2005) Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436, 660-665.
16. Campisi J & d'Adda di Fagagna F. (2007) Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8, 729-740.
17. Collado M, Blasco MA & Serrano M. (2007) Cellular senescence in cancer and aging. Cell 130, 223-233.
18. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C et al. (2006) Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444, 638-642.
19. Dialynas GK, Vitalini MW & Wallrath LL. (2008) Linking heterochromatin protein 1 (HP1) to cancer progression. Mutat Res 647, 13-20.
20. Doil C, Mailand N, Bekker-Jensen S, Menard P, Larsen DH, Pepperkok R et al. (2009) RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins. Cell 136, 435-446.
21. Dormann HL, Tseng BS, Allis CD, Funabiki H & Fischle W. (2006) Dynamic regulation of effector protein binding to histone modifications: the biology of HP1 switching. Cell Cycle 5, 2842-2851.
22. Fernandez-Capetillo O, Mahadevaiah SK, Celeste A, Romanienko PJ, Camerini-Otero RD, Bonner WM, Manova K, Burgoyne P & Nussenzweig A. (2003) H2AX is required for chromatin remodeling and inactivation of sex chromosomes in male mouse meiosis. Dev Cell 4, 497-508.
23. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T et al. (2005) Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434, 907-913.
24. Halazonetis TD, Gorgoulis VG & Bartek J. (2008) An oncogene-induced DNA damage model for cancer development. Science 319, 1352-1355.
25. Handel MA. (2004) The XY body: a specialized meiotic chromatin domain. Exp Cell Res 296, 57-63.
26. Hofken K & Lauke H. (1996) Mitotic frequency in different early stages of testicular seminoma. Andrologia 28, 335-341.
27. Jackson SP & Bartek J. (2009) The DNA damage response in human biology and disease. Nature 461, 1071-1078.
28. Jensen SS, Madsen MW, Lukas J, Binderup L & Bartek J. (2001) Inhibitory effects of 1α, 25-dihydroxyvitamin D3 on the G1-S phase controlling machinery. Mol Endocrinol 15, 1370-1380.
29. Kirschmann DA, Lininger RA, Gardner LM, Seftor EA, Odero VA, Ainsztein AM, Earnshaw WC, Wallrath LL & Hendrix MJ. (2000) Down-regulation of HP1Hsalpha expression is associated with the metastatic phenotype in breast cancer. Cancer Res 60, 3359-3363.
30. Luijsterburg MS, Dinant C, Lans H, Stap J, Wiernasz E, Lagerwerf S et al. (2009) Heterochromatin protein 1 is recruited to various types of DNA damage. J Cell Biol 185, 577-586.
31. Mallette FA, Gaumont-Leclerc MF & Ferbeyre G. (2007) The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev 21, 43-48.
32. Metzler-Guillemain C, Luciani J, Depetris D, Guichaoua MR & Mattei MG. (2003) HP1beta and HP1gamma, but not HP1alpha, decorate the entire XY body during human male meiosis. Chromosome Res 11, 73-81.
33. Motamedi MR, Hong EJ, Li X, Gerber S, Denison C, Gygi S & Moazed D. (2008) HP1 proteins form distinct complexes and mediate heterochromatic gene silencing by non-overlapping mechanisms. Mol Cell 32, 778-790.
34. Nakamura AJ, Chiang YJ, Hathcock KS, Horikawa I, Sedelnikova OA, Hodes RJ & Bonner WM. (2008) Both telomeric and non-telomeric DNA damage are determinants of mammalian cellular senescence. Epigenetics Chromatin 1, 6, doi.
35. Narita M, Nunez S, Heard E, Lin AW, Hearn SA, Spector DL, Hannon GJ & Lowe SW. (2003) Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113, 703-716.
36. Oosterhuis JW & Looijenga LHJ. (2005) Testicular germ-cell tumours in a broader perspective. Nat Rev Cancer 5, 210-222.
37. Panteleeva I, Boutillier S, See V, Spiller DG, Rouaux C, Almouzni G et al. (2007) HP1α guides neuronal fate by timing E2F-targeted genes silencing during terminal differentiation. EMBO J 26, 3616-3628.
38. Probst AV, Dunleavy E & Almouzni G. (2009) Epigenetic inheritance during the cell cycle. Nat Rev Mol Cell Biol 10, 192-206.
39. Rajpert-De Meyts E. (2006) Developmental model for the pathogenesis of testicular carcinoma in situ: genetic and environmental aspects. Hum Reprod Update 12, 303-323.
40. Rajpert-De Meyts E, Bartkova J, Samson M, Hoei-Hansen CE, Frydelund-Larsen L, Bartek J & Skakkebæk NE. (2003) The emerging phenotype of the testicular carcinoma in situ cell. APMIS 111, 267-279.
41. Sedivy JM, Banumathy G & Adams PD. (2008) Aging by epigenetics - a consequence of chromatin damage? Exp Cell Res 314, 1909-1917.
42. Skakkebæk NE, Berthelsen JG, Giwercman A & Müller J. (1987) Carcinoma-in-situ of the testis: possible origin from gonocytes and precursor of all types of germ cell tumours except spermatocytoma. Int J Androl 10, 19-28.
43. Sonne SB, Almstrup K, Dalgaard M, Juncker AS, Edsgard D, Ruban L et al. (2009) Analysis of gene expression profiles of microdissected cell populations indicates that testicular carcinoma in situ is an arrested gonocyte. Cancer Res 69, 5241-5250.
44. Strohmeyer T, Reissmann P, Cordon-Cardo C, Hartmann M, Ackermann R & Slamon D. (1991) Correlation between retinoblastoma gene expression and differentiation in human testicular tumors. Proc Natl Acad Sci USA 88, 6662-6666.
45. Takanashi M, Oikawa K, Fujita K, Kudo M, Kinoshita M & Kuroda M. (2009) Heterochromatin protein 1γ epigenetically regulates cell differentiation and exhibits potential as a therapeutic target for various types of cancers. Am J Pathol 174, 309-316.
46. Woodward PJ, Heidenreich A, Looijenga LHJ, Oosterhuis JW, McLeod DG, Møller H et al. (2004) Germ cell tumours. In: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs (eds JN Eble, G Sauter, JI Epstein & IA Sesterhenn), chapter 4, pp. 217-249. IARC Press, Lyon.
47. Ye X, Zerlanko B, Zhang R, Somaiah N, Lipinski M, Salomoni P & Adams PD. (2007) Definition of pRB- and p53-dependent and-independent steps in HIRA/ASF1a-mediated formation of senescence-associated heterochromatin foci. Mol Cell Biol 27, 2452-2465.
48. Zamudio NM, Chong S & O'Bryan MK. (2008) Epigenetic regulation in male germ cells. Reproduction 136, 131-146.
49. Zhang R & Adams PD. (2007) Heterochromatin and its relationship to cell senescence and cancer therapy. Cell Cycle 6, 784-789.